Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
about
Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporterAnandamide uptake by synaptosomes from human, mouse and rat brain: inhibition by glutamine and glutamateEndocannabinoid system: emerging role from neurodevelopment to neurodegeneration.TRPV1: A Potential Drug Target for Treating Various Diseases.A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.The endocannabinoid system as a target for the treatment of neurodegenerative disease.Calpain cleavage of brain glutamic acid decarboxylase 65 is pathological and impairs GABA neurotransmission.Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.Regulation of neurite outgrowth by G(i/o) signaling pathways.The therapeutic potential of the cannabinoids in neuroprotection.The therapeutic potential of cannabinoids for movement disorders.Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Tardive dyskinesia and essential fatty acids.Drugs of abuse and the aging brain.The endocannabinoid system as a target for the treatment of motor dysfunction.The therapeutic potential of novel cannabinoid receptorsMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Prospects for cannabinoid therapies in basal ganglia disorders.Endocannabinoid system in neurodegenerative disorders.AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide.Cannabinoids for the Treatment of Movement Disorders.Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors.Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
P2860
Q24644993-8E63A423-379F-493D-A8B0-2D70AFCC16AEQ24793780-46B7EB9E-19FE-44A1-B53C-9FE89F29E99BQ30391852-227EB64D-61B8-4403-B0FA-287D2C795B55Q30434994-0324D35F-7F34-4762-B871-8360B8AB62A8Q34011553-81946AB5-92DD-4829-91E5-314C58BF2AC5Q34098196-90B06802-7D37-4535-A05C-3971883C63CAQ34200288-82564829-8980-4F1F-BDE6-F3F3FEE84B75Q34320147-6122972F-C21D-4243-9F84-071939F57936Q34746354-2DACAF05-35AA-4A73-AC8E-463C0C142FD2Q34974856-E194F8B3-0B2A-4C1D-BFF5-14961450F8EDQ35171113-1E02F7F5-E0C5-4C63-BD00-71BE523CE80AQ36155898-BA9D7464-EAB3-4D63-8D25-259BA52F28B2Q36157657-B047F142-571B-446D-A5A2-B676DA3DF432Q36341688-27DA8CA9-3F9C-4721-B2F0-CA4195837829Q36508056-6491A841-79E5-46AA-A997-96553F909267Q36779439-4F88CAC4-9E1B-4E79-A6F9-9DF5ECBEB6FDQ37394164-DEE9EF64-BD00-46FB-B890-B2EF27BAA6C6Q37402927-9526241B-9062-415A-A7CA-1CF1EB82EB53Q37512670-3821C682-301A-4A58-8C9E-E21C75BE950CQ37872326-232CE240-7FCA-4194-A1B2-FAD4072306CEQ39368845-0DDCB7C3-38F3-45A2-BF25-8CF584C91337Q40654914-4F3E9C9D-F23F-4950-9CBF-EB1FE97B776AQ40701861-4E4CFE5E-E30B-4870-BD5D-8A5E762272C0Q41969953-B175F272-5E7C-49FA-828B-773B85F086A7Q44186888-0F7DED70-8398-4C97-9063-42FC2BDD0546Q45303268-106568F7-E003-4E0A-AF34-CB307FCC0AE6Q55387906-4643386E-DAE0-43BA-8757-0EFF5D00CCC8
P2860
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Alleviation of motor hyperacti ...... model of Huntington's disease.
@en
Alleviation of motor hyperacti ...... model of Huntington's disease.
@nl
type
label
Alleviation of motor hyperacti ...... model of Huntington's disease.
@en
Alleviation of motor hyperacti ...... model of Huntington's disease.
@nl
prefLabel
Alleviation of motor hyperacti ...... model of Huntington's disease.
@en
Alleviation of motor hyperacti ...... model of Huntington's disease.
@nl
P2093
P2860
P356
P1433
P1476
Alleviation of motor hyperacti ...... model of Huntington's disease
@en
P2093
Alberto Pérez-Rosado
Fernando Berrendero
Henrik H Hansen
Javier Fernández-Ruiz
Jorge Manzanares
José A Ramos
Rosario De Miguel
P2860
P356
10.1002/SYN.10054
P577
2002-04-01T00:00:00Z